|Day Low/High||2.51 / 2.75|
|52 Wk Low/High||0.49 / 3.38|
The psychedelic therapeutics biotech pulled in an additional $30 million in Canadian dollars; let's figure out why and what it means -- and why it's kinda weird.
Cybin Inc. and Draganfly Inc. soon will move up from the OTC markets to a major exchange; here are their prospects going forward.
With a portfolio of 10 names that fit this category, I only need to be correct on one to be profitable. If I hit on more than one, I'm crushing it. And if I hit on three...
What they both have in common is a ton of momentum in their respective businesses.
The goal is to create a stock replacement style of approach but one that could provide unlimited upside.
Let's look at seven names that you can buy right now and watch grow.
This has given investors an opportunity to load up on small speculative names I love over the next 12 to 18 months.
There are much better places an investor can put their hard-earned cash, whether they want an aggressive or a moderate name.
The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.
Dealmaking is going strong and looks set to continue as mental health becomes a key investment theme going forward.